By Chris Larson | August 4, 2023
The Drug Enforcement Administration (DEA) has openly signaled a reversal in its stance towards a long-mandated special registration process that would allow telehealth prescribing of certain controlled substances.
In a newly published meeting notice, the DEA says the voluminous and negative feedback on its proposed rule for post-public health emergency telehealth regulations inspired its new consideration of a special registration process.
The meeting notice calls for two public comment listening sessions on Sept. 12 and 13. These listening sessions are intended to inform the DEA on preventing and detecting the diversion of controlled substances prescribed via telehealth.